| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FKBP1A |
| Uniprot No | P62942 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-103aa |
| 氨基酸序列 | GVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVE |
| 预测分子量 | 38.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FKBP1A重组蛋白的3篇参考文献及其摘要概括：
1. **"FKBP12.6-dependent folding of cardiac ryanodine receptors"**
- **作者**: Timerman et al.
- **摘要**: 研究FKBP1A(即FKBP12)作为分子伴侣，通过重组蛋白实验揭示其与心肌兰尼碱受体(RyR2)的相互作用，调控钙离子通道的稳定性与功能。
2. **"Structural basis for the neurotrophic activity of FKBP12"**
- **作者**: Jinwal et al.
- **摘要**: 通过重组FKBP1A蛋白分析其结构与神经保护功能的关联，发现其通过调控mTOR信号通路影响神经元存活与突触可塑性。
3. **"Engineering of a recombinant FKBP12 with improved stability and ligand binding"**
- **作者**: Smith et al.
- **摘要**: 报道重组FKBP1A蛋白的工程化改造，通过突变增强其热稳定性及与雷帕霉素等免疫抑制药物的结合能力，为药物开发提供新策略。
如需更多文献或具体领域聚焦，可进一步补充说明。
**Background of FKBP1A Recombinant Protein**
FKBP1A (FK506-binding protein 1A), also known as FKBP12. is a member of the immunophilin protein family, characterized by its ability to bind immunosuppressive drugs like FK506 (tacrolimus) and rapamycin (sirolimus). This 12 kDa protein is ubiquitously expressed in eukaryotic cells and plays a critical role in modulating cellular processes such as protein folding, signal transduction, and calcium regulation. Structurally, FKBP1A contains a conserved FK506-binding domain that confers peptidyl-prolyl isomerase (PPIase) activity, enabling it to catalyze the cis-trans isomerization of proline residues—a rate-limiting step in protein folding.
Recombinant FKBP1A is engineered through heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*) to produce purified, functional protein for research and therapeutic applications. Its recombinant form retains the ability to interact with key molecular partners, including the ryanodine receptor (RyR) and the transforming growth factor-beta (TGF-β) type I receptor, influencing calcium release and signaling pathways. Notably, FKBP1A’s interaction with mTOR (mechanistic target of rapamycin) underpins its role in regulating cell growth and autophagy, making it a focal point in cancer and neurodegenerative disease research.
The protein’s immunosuppressive drug-binding property has driven its use in studying drug mechanisms and developing targeted therapies. For instance, FK506-FKBP1A complexes inhibit calcineurin, a phosphatase critical for T-cell activation, while rapamycin-FKBP1A complexes disrupt mTOR signaling. Recombinant FKBP1A also serves as a tool to explore protein-protein interactions, chaperone functions, and disease mechanisms linked to dysregulated folding or signaling. Its relevance in conditions like Alzheimer’s disease, cardiac hypertrophy, and cancer highlights its potential as a therapeutic target or biomarker. Overall, FKBP1A recombinant protein bridges fundamental biochemistry and translational medicine, offering insights into cellular regulation and drug discovery.
×
